Dronabinol

Dronabinol is essentially pharmaceutical-grade delta-9-THC in a capsule or oral drop; it is pretty much the cleanest, most standardized way to get the exact same molecule that drives cannabis, minus the smoke and the guesswork on dose. The appetite and anti-nausea data are hands down its strongest suit; the classic AIDS-anorexia trial showed it reliably nudged appetite up and steadied weight, and head-to-head against ondansetron it held its own for delayed chemo nausea.

The appeal is that it is a known quantity with real FDA labeling behind it; you know precisely what you are taking. Just be honest with yourself; it is orally dosed THC, so the psychoactivity, the slow oral onset, and the dizziness are part of the package, and megestrol tends to beat it for raw weight gain in wasting syndromes. For the person who wants the endocannabinoid benefits with a clinical paper trail, it is a solid, above-board option.

Dronabinol is a controlled substance and a psychoactive drug; common adverse effects are dose-related and central, including euphoria, dizziness, somnolence, abnormal thinking, and, less often, anxiety, paranoia, or hallucinations. Cardiovascular effects such as tachycardia and orthostatic hypotension can occur, particularly at initiation and in older patients. It should be used cautiously with other CNS depressants and in people with cardiac disease, psychiatric history, or substance-use disorder. In cancer- and HIV-associated wasting, comparative trials found megestrol acetate produced greater weight gain than dronabinol. It is not risk-free, but adverse effects in appetite and antiemetic trials were generally mild to moderate, and discontinuation rates were similar to placebo.

Food significantly affects dronabinol (THC) absorption and plasma concentrations through a pharmacokinetic food-drug interaction. Administration with a fatty meal increases THC area under the curve 1 to 3-fold and delays the peak concentration time approximately 2-2.5 hours ^[7]. The active metabolite 11-hydroxy-THC similarly increases with food. Additionally, cannabis terpenes naturally present in some cannabis products exhibit pharmacodynamic synergism with THC at cannabinoid CB1 and CB2 receptors; terpenes like limonene, sabinene, and beta-caryophyllene potentiate THC-induced receptor activation above what would be predicted from additive effects alone ^[8].

The clinical relevance of terpene interactions is variable depending on product formulation and terpene profile. Interactions not extensively studied include dronabinol with specific medications that compete for hepatic metabolism, concurrent use of other CNS depressants beyond general pharmacology descriptions, and long-term polypharmacy patterns in chronic cannabis users.

Checking a whole stack? Run it through interactions + stacks.